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Past
events
Founded in 1986, IBA mission is to Protect, Enhance and Save 
Lives. At IBA, we are a passionate team of professionals dedicated 
to developing leading-edge technologies to fight cancer, a disease 
that affects us all, either directly or indirectly.
With its cyclotrons for PET & SPECT radio-tracers, Synthera 
labeling modules and the Integralab concept, IBA provides all 
the expertise needed to create your own radio-pharmacy and 
produce radiopharmaceuticals for Nuclear Medicine Depart-
ments, thus providing our contribution in the diagnosis of cancer 
http://www.iba-molecular.com.
More precise dose delivery, fewer side effects, better re-
sults — IBA Proton Therapy is changing the way cancer is treated. 
As the worldwide leader in developing Proton Therapy systems, 
our groundbreaking innovations and flexible solutions are making 
Proton Therapy a reality for more doctors, more communities and 
more patients.
To date, IBA has been selected to install 24 proton therapy 
centers of which 11 are currently treating patients and 9 are 
under installation or construction. IBA’s installations repre-
sent more than half of the clinically based proton therapy 
facilities in the world. The IBA PROTEUS-230 concept, already 
sold, installed and in operation throughout the world, including 
Essen, Orsay, Trento, Prague, Dresden, Krakow, Upsalla and 
Dimitrovgrad is offering to Radiotherapy Departments the most 
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experienced system commercially available in term of patient 
treatments with protons.
The system is delivered with different treatment rooms like: 
fixed beam room, eye line, inclined beam line and 360° Gantry, 
offering maximum flexibility to the clinicians. The Universel Nozzle 
(four beam modes available, including scattering and scanning 
modes) and the Pencil Beam Scanning Nozzle (IMPT) are pro-
posed to equip the treatment room.
With the development of a CBCT solution, IBA proposes to 
the market an integrated solution in which 3D patient imaging at 
the treatment point will be available. 
Finally, IBA announced at last ASTRO in October 2010, the 
development of a more compact system, named Proteus ONE™*, 
built on a new supra-conductive synchrocyclotron and a compact 
gantry. IBA engineers and designers have spent more than a year 
devising Proteus ONE™*, a smaller, more costeffective Proton 
Therapy system. The new design also simplifies deployment of 
multi-room facilities, requires less land and leaves a smaller footprint.
http://www.iba-protontherapy.com/proteus-one 
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